Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape
The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.
You may also be interested in...
Updated data from PIVOT-02 at the ASCO GU meeting suggest a path for accelerated approval of the NKTR-214/Opdivo combination as first-line treatment of patients with PD-L1-negative urothelial cancers.
The cancer immunotherapy combo showed "remarkable" effects in patients who tested negative for PD-L1 expression and would normally not respond well to immunotherapy.
Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.